Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

JSON

Jädersten M, Boriskina K, Lindholm C, Weström S, Cavelier L, Hellström-Lindberg E, Mielke S, Tobiasson M

Leuk. Lymphoma 63 (3) 755-758 [2022-03-00; online 2021-11-15]

PubMed 34775885

DOI 10.1080/10428194.2021.2002319

Crossref 10.1080/10428194.2021.2002319

SciLifeLab Data Centre
Publications 9.5.1